{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"","title":"Best Of: Inside Johnson & Johnson’s bankruptcy two-step","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/615edd9c0cb78d1a6bda37d9/1653426925492-d0e5b9f095017884c93fe94bcacaacbe.jpeg?height=200","description":"

This week, we’re revisiting an episode from last year. Johnson & Johnson, one of the world’s largest healthcare companies, is facing thousands of lawsuits from people alleging they got cancer from using one of their oldest products: talc-based baby powder. To manage the growing liability, J&J deployed a controversial bankruptcy manoeuvre known as the Texas two-step. The FT’s US pharmaceutical correspondent Jamie Smyth helps us explore whether J&J’s use of this manoeuvre is setting a precedent for corporations to evade accountability in America. Plus, stick around for an update on what’s happened to the Texas two-step since this episode first aired. 


Clip from NBC 


- - - - - - - - - - - - - - - - - - - - - - - - - - 

For further reading:

Johnson & Johnson’s ‘Texas-two-step’ sparks outcry over US bankruptcy regime

Talc ruling a blow to J&J and the ‘Texas two-step’ bankruptcy jig

Talcum powder cancer claims target J&J’s new consumer carve-out

- - - - - - - - - - - - - - - - - - - - - - - - - - 

On Twitter, follow Jamie Smyth (@JamieSmythF) and Michela Tindera (@mtindera07)


Read a transcript of this episode on FT.com


","author_name":"Financial Times"}